UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 52

Sortiert nach

Therapie des metastasierten Pankreaskarzinoms

Der Onkologe, 2015-11, Vol.21 (11), p.1044-1053

2015

Link zum Volltext

Verfügbarkeit prüfen

EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity

Annals of oncology, 2018-04, Vol.29 (4), p.1010-1015

2018

Link zum Volltext

Verfügbarkeit prüfen

MIRACLE: Green tea extract versus placebo for the prevention of colorectal adenomas: A randomized, controlled trial

Annals of oncology, 2019-10, Vol.30, p.v869

2019

Link zum Volltext

Verfügbarkeit prüfen

Reply to the Letter to the Editor ‘The Neonax study’ by M. W. Büchler and J. Neoptolemos

Annals of oncology, 2023-04, Vol.34 (4), p.443-445

2023

Link zum Volltext

Verfügbarkeit prüfen

6568 POSTER DocOX – a Phase II Trial With Docetaxel and Oxaliplatin as a 2nd-line Systemic Therapy for Patients With Advanced And/or Metastatic Adenocarcinoma of the Pancreas – Interim Analysis

European journal of cancer (1990), 2011, Vol.47, p.S461-S461

2011

Link zum Volltext

Verfügbarkeit prüfen

Metastasiertes kolorektales Karzinom

Onkologie (Heidelberg, Germany), 2016-02, Vol.22 (2), p.109-114

2016

Link zum Volltext

Verfügbarkeit prüfen

1641P ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer

Annals of oncology, 2023-10, Vol.34, p.S907-S907

2023

Link zum Volltext

Verfügbarkeit prüfen

NIFE-trial: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced biliary-tract cancer: An open label, randomized, multicenter phase II trial of the AIO

Annals of oncology, 2017-09, Vol.28, p.v264-v264

2017

Link zum Volltext

Verfügbarkeit prüfen

424P Pembrolizumab and olaparib in advanced HER2-negative esophagogastric adenocarcinoma: First results of the phase II AIO IKF-038/POLESTAR trial

Annals of oncology, 2024-06, Vol.35, p.S172-S173

2024

Link zum Volltext

Verfügbarkeit prüfen

386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)

Annals of oncology, 2024-06, Vol.35, p.S155-S155

2024

Link zum Volltext

Verfügbarkeit prüfen

191P Evaluating sorafenib as second-line treatment for advanced hepatocellular carcinoma: SORA-2, an European retrospective multicenter study

Annals of oncology, 2024-06, Vol.35, p.S86-S86

2024

Link zum Volltext

Verfügbarkeit prüfen

Multicenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114)

Annals of oncology, 2019-10, Vol.30, p.v303

2019

Link zum Volltext

Verfügbarkeit prüfen

787P - Multicenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114)

Annals of oncology, 2019-10, Vol.30, p.v303-v303

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

European journal of cancer (1990), 2018-05, Vol.94, p.95-103

2018

Link zum Volltext

Verfügbarkeit prüfen

LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)

Annals of oncology, 2021-09, Vol.32, p.S1312-S1312

2021

Link zum Volltext

Verfügbarkeit prüfen

Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)

Annals of oncology, 2019-10, Vol.30, p.v219

2019

Link zum Volltext

Verfügbarkeit prüfen

580P - Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)

Annals of oncology, 2019-10, Vol.30, p.v219-v219

2019

Link zum Volltext

Verfügbarkeit prüfen

1624P Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)

Annals of oncology, 2023-10, Vol.34, p.S899-S900

2023

Link zum Volltext

Verfügbarkeit prüfen

LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group

Annals of oncology, 2021-09, Vol.32, p.S1282-S1282

2021

Link zum Volltext

Verfügbarkeit prüfen

LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study

Annals of oncology, 2021-09, Vol.32, p.S1333-S1333

2021

Link zum Volltext

Verfügbarkeit prüfen

A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma

Annals of oncology, 2018-10, Vol.29, p.viii663-viii663

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(52)

Sprache

Erscheinungsjahr

n.n

Thema

Oncology
(11)
Humans
(8)
Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Medicine
(5)
Medicine & Public Health
(5)
Prospective Studies
(5)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Colorectal Cancer
(3)
Colorectal Neoplasms - Drug Therapy
(3)
Family Medicine
(3)
Female
(3)
Gastroenterology
(3)
Gemcitabine
(3)
General Practice
(3)
Hepatology
(3)
Internal Medicine
(3)
Male
(3)
Original Research
(3)
Pancreatic Cancer
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Therapie des metastasierten Pankreaskarzinoms

EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity

MIRACLE: Green tea extract versus placebo for the prevention of colorectal adenomas: A randomized, controlled trial

Reply to the Letter to the Editor ‘The Neonax study’ by M. W. Büchler and J. Neoptolemos

6568 POSTER DocOX – a Phase II Trial With Docetaxel and Oxaliplatin as a 2nd-line Systemic Therapy for Patients With Advanced And/or Metastatic Adenocarcinoma of the Pancreas – Interim Analysis

Metastasiertes kolorektales Karzinom

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group

1641P ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer

NIFE-trial: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced biliary-tract cancer: An open label, randomized, multicenter phase II trial of the AIO

424P Pembrolizumab and olaparib in advanced HER2-negative esophagogastric adenocarcinoma: First results of the phase II AIO IKF-038/POLESTAR trial

386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)

191P Evaluating sorafenib as second-line treatment for advanced hepatocellular carcinoma: SORA-2, an European retrospective multicenter study

Multicenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114)

787P - Multicenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114)

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

1535P Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO

LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)

Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)

580P - Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)

1624P Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)

LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group

LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study

1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO

A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma

Suchergebnisse filtern